Argenx SE Announces AGM Results and Key Resolutions

Argenx Se ( (ARGX) ) has provided an announcement.

On May 28, 2025, Argenx SE announced the results of its Annual General Meeting held on May 27, 2025, where 91.1% of the company’s share capital was represented. All agenda items received the required majority of votes except for the adoption of the remuneration policy, which fell short with a 73% majority. Key resolutions included the approval of the 2024 remuneration report, annual report, and accounts, the re-appointment of Anthony Rosenberg as non-executive director, and the authorization for the Board to issue shares and grant rights for up to 10% of the outstanding share capital.

The most recent analyst rating on (ARGX) stock is a Buy with a $514.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

Spark’s Take on ARGX Stock

According to Spark, TipRanks’ AI Analyst, ARGX is a Neutral.

Argenx Se scores a 69, driven by strong financial performance with substantial revenue growth and a solid balance sheet. The positive sentiment from the earnings call highlights successful product launches and strategic advancements. However, the stock faces challenges from a bearish technical outlook and high valuation, which tempers the overall score.

To see Spark’s full report on ARGX stock, click here.

More about Argenx Se

Argenx SE is a global immunology company dedicated to enhancing the lives of individuals with severe autoimmune diseases. Through its Immunology Innovation Program, the company collaborates with leading academic researchers to transform immunology breakthroughs into a portfolio of novel antibody-based medicines. Argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, exploring its potential across various serious autoimmune diseases, while also advancing several early-stage experimental medicines.

Average Trading Volume: 419,144

Technical Sentiment Signal: Buy

Current Market Cap: $35.63B

See more insights into ARGX stock on TipRanks’ Stock Analysis page.